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ABSTRACT 
We recently reported that (i) activation of the proinflammatory receptor, proteinase-activated 
receptor-2 (PAR-2) caused the release of an important biomarker in preeclampsia, soluble 
vascular endothelial growth factor receptor-1 (sVEGFR-1, also known as sFlt-1) from human 
umbilical vein endothelial cells (HUVECs), and (ii) that the anti-oxidant and anti-inflam-
matory agent, resveratrol, is capable of inhibiting the proinflammatory cytokine-induced 
sVEGFR-1 release from human placenta. Based on these findings and because PAR-2 is up-
regulated by proinflammatory cytokines, we sought to determine whether resveratrol can in-
hibit PAR-2-induced sVEGFR-1 release. PAR-2 expressing cells, HUVECs and human em-
bryonic kidney cells (HEK-293) transfected with a human VEGFR-1 promoter-luciferase re-
porter construct were incubated with PAR-2-activating peptide and/or resveratrol. Cell super-
natants were assayed for sVEGFR-1 by enzyme-linked immunosorbent assay (ELISA), and 
VEGFR-1 promoter-luciferase assay was performed on the harvested cell lysates. Preincuba-
tion of HEK-293 cells with resveratrol significantly inhibited PAR-2-induced VEGFR-1 pro-
moter activity without affecting cell viability as assessed by MTT assay. The addition of 
resveratrol also blocked PAR-2-mediated sVEGFR-1 release from HUVECs. The present 
study demonstrates that resveratrol suppressed both VEGFR-1 promoter activity and 
sVEGFR-1 protein release induced by PAR-2 activation, which further endorses our recent 
findings of a potential therapeutic role for resveratrol in preeclampsia.  
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INTRODUCTION 
Preeclampsia is a pregnancy complicat-
ed disease characterised by aggravated in-
flammation (Rodie et al., 2004) and wide-
spread of maternal endothelial damage with 
a clinical presentation of hypertension and 
proteinuria after 20 weeks gestation that af-
fects about 5 % of all pregnancies and 
women (Sibai et al., 2005). A systematic 
review and meta-analysis has documented 
that women with preeclampsia are at an in-
creased risk of developing cardiovascular 
disease later in life (Bellamy et al., 2007). 
High levels of the anti-angiogenic factor, 
soluble vascular endothelial growth factor 
(VEGF) receptor-1 (sVEGFR-1, commonly 
known as sFlt-1) are observed in pregnan-
cies complicated with preeclampsia 
(Chaiworapongsa et al., 2005; Hertig et al., 
2004; Koga et al., 2003; Levine et al., 
2004). Elevated sVEGFR-1 antagonises the 
action of VEGF and placenta growth factor 
resulting in impaired human placental angi-
ogenesis (Ahmad and Ahmed, 2004) and 
causes glomerular endothelial cell damage, 
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proteinuria and hypertension in rodent 
models (Maynard et al., 2003; Sugimoto et 
al., 2003).  
PAR-2 plays an important role in in-
flammation and regulates vascular function 
(Al-Ani et al., 1995; Steinhoff et al., 2005; 
Vergnolle 1999). Pro-inflammatory cyto-
kines such as TNF and IFN induce PAR-
2 expression and in turn activation of PAR-
2 promotes the production of TNF, IFN, 
IL-8 and IL-18 in various cell types includ-
ing the endothelium and endometrium 
(Cenac et al., 2004; Ikawa et al., 2005; 
Nystedt et al., 1996; Zhu et al., 2006). 
PAR-2 expression is reported to be in-
creased in umbilical vein endothelial cells 
derived from preeclamptic pregnancies, and 
the conditioned medium from preeclamptic 
placental villous tissue explants up-regulate 
PAR-2 in cultured endothelial cells (Wang 
et al., 2002). We recently reported the re-
lease of sVEGFR-1 from endothelial cells 
and an increase in the VEGFR-1 promoter 
activities upon PAR-2 activation (Al-Ani et 
al., 2010). In addition, we also recently re-
ported (Cudmore et al., 2012) that in human 
placenta, the chemical substance obtained 
from the skin of grapes and other fruits, 
resveratrol (Bertilli et al., 1995; Frankel et 
al., 1993; Singh et al., 2011) blocked the re-
lease of sVEGFR-1 from human placenta 
incubated with the proinflammatory cyto-
kine, TNF. Therefore, we speculated that 
resveratrol is capable of suppressing PAR-
2-mediated sVEGFR-1 release and 
VEGFR-1 promoter activity.  
 
MATERIALS AND METHODS 
Reagents 
PAR-2 peptide, 2-furoyl-LIGRLO-NH2 
(2f-LIGRLO) and its reverse control pep-
tide, 2-furoyl-OLRGIL-NH2 (2f-OLRGIL) 
were gift from Professor Morley D Hollen-
berg, Faculty of Medicine, University of 
Calgary, Calgary, Alberta, Canada. Human 
DuoSet VEGFR1 ELISA kit was purchased 
from R&D Systems, UK, and all other cell 
culture reagents and chemicals were ob-
tained from Sigma Aldrich (Poole, UK).  
  
Cell culture 
Human umbilical vein endothelial cells 
(HUVEC) were isolated and cultured as de-
scribed previously (Bussolati et al., 2001). 
Informed consent was obtained from 
healthy pregnant women undergoing elec-
tive caesarean section at Birmingham wom-
en’s hospital under ethical approval 
[RCS10-0546.APP/N10-014]. Cords were 
collected on the day of surgery and washed 
with PBS to remove excessive blood and 
proceed for HUVEC isolation and culture. 
Experiments were performed on second or 
third passage HUVEC. HEK-293 human 
embryonic kidney cells were maintained in 
DMEM containing 10 % FCS.  
 
Enzyme-linked immunosorbent assays  
Enzyme-linked immunosorbent assays 
to determine the concentrations of 
sVEGFR-1 in cell supernatants were per-
formed as described previously (Ahmad 
and Ahmed, 2004) using the human DuoSet 
VEGFR1 ELISA kit according to the manu-
facturer’s instructions (R&D Systems, UK).  
  
MTT assay for cell viability 
HEK-293 cells were seeded at a density 
of 1x 104 cells/well in a 96-well plate and 
incubated overnight at 37 °C in growth me-
dium. Cells were incubated in triplicate 
with resveratrol in medium containing 5 % 
FCS for 24 hours. Then, 5 mg/ml MTT (3-
(4,5-Dimethylthiazol–2-yl)-2,5-diphenylte-
trazolium bromide was added and the plate 
incubated in the dark at 37 °C for 4 hours. 
The MTT solution was removed and 
DMSO (150 l/well) added and the plate 
agitated for 5 minutes. The optical density 
was measured at 570 nm and 630 nm and 
DMSO alone was used as a blank.  
 
VEGFR-1 promoter reporter assays 
As described previously (Al-Ani et al., 
2010), a 1.3 Kb fragment of the human 
VEGFR-1 promoter starting from -1500 bp 
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relative to the start codon was cloned into 
the pGL2 luciferase reporter plasmid 
(pVEGFR-1luc) and was used to determine 
the ability of PAR-2 to activate the 
VEGFR-1 gene in HEK-293 cells which 
express high levels of PAR-2 (Kawabata et 
al., 1999). Luciferase reporter construct was 
introduced into HEK-293 cells using 
ExGen 500 (EuroMedex, France) as de-
scribed previously (Al-Ani et al., 2010). 
Following stimulation for 24 hours, lucifer-
ase activity was determined in cell lysates 
using the Dual Luciferase Assay (Promega) 
as described previously (Al-Ani et al., 
2010). 
 
Statistical analysis 
All data are expressed as the mean ± 
SEM. Statistical analysis was performed us-
ing the two-tailed Student’s t-test and 
p < 0.05 was considered statistically signif-
icant. 
 
RESULTS 
To investigate whether the anti-inflam-
matory agent, resveratrol, can inhibit PAR-
2-mediated activation of VEGFR-1 gene 
promoter, we transfected HEK-293 cells 
that express PAR-2 with a plasmid DNA 
construct carrying 1300 bp human VEGFR-
1 promoter luciferase reporter (Al-Ani et 
al., 2010). As expected, activation of PAR-
2 with 10 mol/L 2f-LIGRLO-NH2 peptide 
caused more than a 2-fold increase in 
VEGFR-1 promoter activity, which was 
almost completely blocked by resveratrol 
(Figure 1, A). Resveratrol also suppressed 
the basal level of VEGFR-1 promoter activ-
ity in the unstimulated cells (Figure 1A). 
The effect of resveratrol was specific since 
using the same inhibitory dose (25 mol/L) 
was not toxic to HEK-293 cells (Figure 
1B). The control reverse peptide 2f-
OLRGIL-NH2 failed to activate VEGFR-1 
promoter DNA and did not interfere with 
the inhibitory action of resveratrol (data not 
shown).  
Endothelial cells have been shown to 
secrete sVEGFR-1 in response to PAR-2 
activation (Al-Ani et al., 2010). To deter-
mine whether the observed inhibitory effect 
of resveratrol on PAR-2 stimulating 
VEGFR-1 gene can further be extended to 
include inhibition of the release of 
sVEGFR-1 protein, HUVECs were incu-
bated for 24 hours with 10 mol/L 2f-
LIGRLO-NH2 in the presence or absence of 
50 mol/L resveratrol, and sVEGFR-1 was 
assayed in cell supernatants. Resveratrol 
significantly inhibited sVEGFR-1 release  
 
Figure 1: Resveratrol inhibits PAR-2-induced 
activation of the VEGFR-1 gene promoter.  
A: HEK-293 cells transfected with a ~1.3 kb 
fragment of the VEGFR-1 promoter with a lucif-
erase reporter were incubated with the specific 
PAR-2 activator, 2f-LIGRLO-NH2 (10 mol/L) 
for 24 hours in the presence and absence of 25 
mol/L resveratrol. VEGFR-1 promoter activi-
ties in cell lysates were determined by lucifer-
ase assay.  
B: HEK-293 cells were incubated for 24 hours 
with increasing concentrations of resveratrol in 
medium containing 5 % FCS and cell viability 
assessed by MTT assay. Results represent the 
mean (±SEM). *, p < 0.01 vs control for (A) and 
*, p < 0.05 vs control for (B) 
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under basal condition and after stimulation 
(Figure 2, A). The control reverse peptide 
2f-OLRGIL-NH2 caused no release of 
sVEGFR-1 and did not interfere with the 
action of resveratrol (Figure 2, B). We have 
shown before that resveratrol up to 100 
mol/L were not toxic to HUVECs (Cud-
more et al., 2012). 
 
DISCUSSION 
The present report demonstrates that 
resveratrol, found in high concentrations in 
the skin of red grapes, inhibits VEGFR-1 
promoter activation by PAR-2. Further-
more, it shows that resveratrol suppresses 
PAR-2-induced sVEGFR-1 release from 
endothelial cells and supports our recent 
study showing that resveratrol inhibits cy-
tokine-induced sVEGFR-1 release from 
human placenta (Cudmore et al., 2012). 
 
Figure 2: Resveratrol inhibits PAR-2-induced 
sVEGFR-1 release. HUVECs were incubated 
with (A) 10 µmol/L 2f-LIGRLO-NH2 or (B) 
10 mol/L 2f-OLRGIL-NH2 control peptide for 
24 hours in the presence and absence of 
50 µmol/L resveratrol. Cell supernatants were 
assayed for sVEGFR-1 by ELISA. Results rep-
resent the mean (±SEM). *, p < 0.01 vs control 
vehicle; **, p < 0.01 vs control peptide 
The WHO (2005) reports over 60,000 
maternal deaths worldwide per year as a 
consequence of preeclampsia. Preeclampsia 
is responsible for 30 % of all premature de-
liveries, and delivery of the baby and the 
placenta is still the only available effective 
therapy (Haram et al., 2003). We suggested 
before (Al-Ani et al., 2010) that activation 
of PAR-2 may be a contributing factor to 
the increases in the circulating levels of 
sVEGFR-1 in preeclampsia. This was based 
on the increased procoagulation activity in 
this syndrome and the ability of the coagu-
lation proteinases to activate PAR-2 (Kai-
bara et al., 1999; Manithody et al., 2012; 
Rowland et al., 2000; Wang et al., 2002). 
Furthermore, our reports on the augmenta-
tion of PAR-2-mediated sVEGFR-1 levels 
upon inhibition of heme oxygenase 1 (HO-
1) enzyme (Al-Ani et al., 2010) and that 
higher levels of sVEGFR-1 were secreted 
from lung biopsy explants of HO-1 knock-
out mice compared with wild-type litter 
mates (Cudmore et al., 2007) suggesting 
that HO-1 is a negative regulator of PAR-2-
mediated sVEGFR-1 release in endothelial 
cells and loss of HO-1 activity may be cen-
tral to the pathogenesis of preeclampsia. 
Therefore, our recent publication in this 
field that resveratrol upregulates HO-1 
(Cudmore et al., 2012) would strengthen 
the finding in this study showed resveratrol 
inhibited PAR-2-induced sVEGFR-1 re-
lease and would further promote resveratrol 
as a potential drug to ameliorate the symp-
toms of preeclampsia.  
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